Clinical trials: Rheumatoid
Rheumatoid Arthritis
Standard Versus High Dose Inactivated Influenza Vaccine in RA
Patients with rheumatoid arthritis have increased risk of seasonal influenza and influenza-related complications but have reduced vaccine immunogenicity.
- Trial name
- IV-RA (NCT02936180)
- Testing
- HD-TIV, SD-QIV
- Where
- Canada
- Volunteers
- 279 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Rheumatoid Arthritis
A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis
The purpose of this study is to learn how different types of medicines may improve disease activity in people with rheumatoid arthritis (RA). RA is a kind of joint disease that causes pain and swelling.
- Trial name
- NCT06418529
- Testing
- tofacitinib, tumor necrosis factor inhibitors (TNFi), abatacept
- Where
- United States
- Volunteers
- 21,340 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis
To compare the effects of the combination of ETN and MTX to MTX alone on radiographic change and clinical disease activity in subjects with early RA over 12 months.
- Trial name
- NCT00195494
- Testing
- Etanercept, Methotrexate
- Where
- United States
- Volunteers
- 542 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Arthritis, Rheumatoid
Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects With Rheumatoid Arthritis
The purpose of this study is to examine the effects of etanercept (10 mg and 25 mg) compared with methotrexate (up to 8 mg per week) on the slowing of joint destruction.
- Trial name
- NCT00445770
- Testing
- Etanercept, Methotrexate
- Where
- 41 sites in Japan
- Volunteers
- 550 people
- Sponsor
- Pfizer
Arthritis, Rheumatoid
Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate
CE-224,535 is known to block a chemical that acts as a gateway to some of your immune cells. Blocking this gateway prevents the cells from pushing out 2 chemicals called IL-1 and IL-18 that are known to cause some of the…
- Trial name
- NCT00628095
- Testing
- CE-224,535
- Where
- 27 sites in United States, Chile and 5 more
- Volunteers
- 100 people
- Sponsor
- Pfizer
Arthritis, Rheumatoid
Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid Arthritis
This is a 2-part study to examine the effect of Acthar Gel in adult participants with rheumatoid arthritis (RA) with persistently active disease even after receiving two other treatments intended to modify the disease.
- Trial name
- NCT02919761
- Testing
- Acthar Gel
- Where
- 59 sites in United States, Argentina and 3 more
- Volunteers
- 259 people
- Sponsor
- Mallinckrodt
Arthritis, Rheumatoid
A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate
This study is designed to provide safety and efficacy data to support the development of CP-690,550 in patients with moderate to severe rheumatoid arthritis on background of methotrexate.
- Trial name
- NCT00847613
- Testing
- CP-690,550
- Where
- 115 sites in United States, Australia and 13 more
- Volunteers
- 800 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Non-biological DMARDs
This randomized, double-blind, placebo-controlled study will use Magnetic Resonance Imaging (MRI) to assess the efficacy of tocilizumab plus non-biological DMARD in patients with moderate to severe rheumatoid arthritis who have…
- Trial name
- NCT01034397
- Testing
- tocilizumab [RoActemra/Actemra], non-biological DMARDs
- Where
- 11 sites in Portugal
- Volunteers
- 54 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Good EULAR Response In Patients With Early Rheumatoid Arthritis
This open-label, prospective, observational study will evaluate the clinical response to etanercept + methotrexate therapy in patients with moderate to severe rheumatoid arthritis, as prescribed by the rheumatologist in a normal…
- Trial name
- EARLY RA (NCT01558089)
- Testing
- etanercept, methotrexate
- Where
- 9 sites in Greece
- Volunteers
- 76 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy
The purpose of this study is to determine the PK/PD, efficacy and safety of GP2013 in patients with severe rheumatoid arthritis.
- Trial name
- NCT01274182
- Testing
- GP2013, MabThera, Rituxan
- Where
- 57 sites in United States, Argentina and 12 more
- Volunteers
- 312 people
- Sponsor
- Sandoz
Rheumatoid Arthritis
Clinical Outcomes, Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab in Patients With Active Rheumatoid Arthritis (RA). A Multicenter Post-Marketing Observational Study in Routine Clinical Use
This is a prospective, single-arm, post marketing observational study in adult patients with active rheumatoid arthritis (RA) who are discontinuing treatment due to lack of efficacy, intolerance or to an incomplete response with…
- Trial name
- FALLA (NCT01083160)
- Where
- 12 sites in Mexico
- Volunteers
- 82 people
- Sponsor
- Abbott
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additional doses of COVID-19 vaccine in participants with autoimmune disease requiring IS medications.
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS)
- Trial name
- NCT05000216
- Testing
- Moderna mRNA-1273, BNT162b2, Ad26.COV2.S
- Where
- 29 sites in United States
- Volunteers
- 258 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER)
This open-label, single arm study will assess the safety and efficacy of RoActem ra/Actemra (tocilizumab) in combination with methotrexate in patients with activ e moderate to severe rheumatoid arthritis who have an inadequate…
- Trial name
- NCT01235507
- Testing
- methotrexate, tocilizumab [RoActemra/Actemra]
- Where
- 3 sites in Bosnia and Herzegovina
- Volunteers
- 71 people
- Sponsor
- Hoffmann-La Roche
Arthritis, Rheumatoid
A Post-Marketing Observational Study to Evaluate the Effectiveness of Adalimumab in Patients With Moderately to Severely Active Rheumatoid Arthritis in China
A post-marketing uncontrolled observational study to explore and describe the effectiveness of adalimumab, as prescribed according to the local product label, in patients with moderately to severely active rheumatoid arthritis…
- Trial name
- NCT01464021
- Where
- 3 sites in China
- Volunteers
- 26 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)
The objectives of this study are to verify the superiority in efficacy (American College of Rheumatology 20%: ACR20) and investigate the pharmacokinetics and safety of CDP870 versus placebo without coadministration of MTX in…
- Trial name
- NCT00791921
- Testing
- CDP870
- Where
- 7 sites in Japan
- Volunteers
- 230 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Sjogren Syndrome, Mixed Connective Tissue Disease
A Study to Evaluate the Safety, Tolerability and Efficacy of MHV370 in Participants With Sjogren's Syndrome (SjS) or Mixed Connective Tissue Disease (MCTD)
This study was a basket trial designed to establish safety, tolerability and efficacy of MHV370 in Sjögren's Syndrome (SjS) and Mixed Connective Tissue Disease (MCTD).
- Trial name
- NCT04988087
- Testing
- MHV370
- Where
- 10 sites in China, Germany and 4 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Rheumatoid
A Study To Investigate And Describe The Treatment Patterns And Effect Of Tofacitinib Indicators For Patients With Rheumatoid Arthritis
This study is to investigate and describe the treatment patterns and effect of tofacitinib indicators for patients with Rheumatoid Arthritis (RA) assessing real world patient data entered in the Corrona RA Registry on or after…
- Trial name
- NCT04721808
- Where
- United States
- Volunteers
- 1,712 people
- Sponsor
- Pfizer
Osteoarthritis, Hip, Fracture of Hip
Post Market Clinical Follow-Up of the Zimmer Stafit Acetabular System
This study is a Post Market Clinical Follow up study to fulfil the post market surveillance obligations according to Medical Device Directive and European Medical Device Vigilance System (MEDDEV) 2.12-2.
- Conditions
- Osteoarthritis, Hip, Fracture of Hip, Avascular Necrosis of Hip, Dislocated Hip
- Trial name
- NCT04079114
- Testing
- Patients who received the Stafit Acetabular System
- Volunteers
- 166 people
- Sponsor
- Zimmer Biomet
Rheumatoid Arthritis
Substudy - Low Dose of Abatacept in Subjects With Rheumatoid Arthritis
The purpose of this exploratory sub-study was to evaluate from a clinical perspective the impact on disease activity of lowering the dose of abatacept from 10 mg/kg to 5 mg/kg in subjects who had achieved remission (Disease…
- Trial name
- NCT00989235
- Testing
- Abatacept
- Volunteers
- 108 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
This study will evaluate the safety and efficacy of MabThera in patients with active rheumatoid arthritis who have had an inadequate response or were intolerant to treatment with methotrexate.
- Trial name
- NCT00934648
- Testing
- rituximab [MabThera/Rituxan], methotrexate
- Where
- 5 sites in Morocco
- Volunteers
- 15 people
- Sponsor
- Hoffmann-La Roche